The RI-INBRE program, entitled “Rhode Island Network
for Excellence in Biomedical and Behavioral Research”, is a state-wide
infrastructure development program.It is supported by a grant from the National Institutes of Health
(NIH), to the University of Rhode Island, with Dr. Zahir Shaikh as the
Principal Investigator and Program Director. The grant supports
biomedical and behavioral research by faculty and students at the
participating institutions in the state through stipends, salaries,
research equipment, research supplies, travel to scientific meetings,
renovation of laboratory space, and student tuition, etc. It also
supports the Summer Undergraduate Research Fellowship (SURF) Program.
Additionally, the grant provides no cost access to research equipment,
software, and related services through the RI-INBRE Centralized Research
Core Facility and the Bioinformatics Core Facility located at the
College of Pharmacy, University of Rhode Island.
As a condition for accepting research support, either
directly through a research award from the RI-INBRE Program, or through
the use of its Core Facilities or services, the beneficiaries are
required to acknowledge the RI-INBRE grant in their scientific meeting
abstracts and publications along with a disclaimer.
Core Facility users are
required to acknowledge specific services and usage in a similar manner.
The acknowledgement may be stated as:
“Research reported in this [publication, release] was supported
by an Institutional Development Award (IDeA) from the National Institute
of General Medical Sciences of the National Institutes of Health under
grant number 8 P20 GM103430-12.”
The NIH also requires that all
investigators comply with the NIH Public Access Policy. This includes
submission to PubMed Central, upon acceptance for publication, an
electronic version of the final peer-reviewed manuscript resulting from
research supported, in whole or in part, with direct costs from NIH,
includingthe use of Core
Facilities. The author's final peer-reviewed manuscript is defined as
the final version accepted for journal publication, and includes all
modifications from the publishing peer review process. Additional
information about this policy is available at
http://publicaccess.nih.gov.
Failure to comply with the above requirements will
result in termination of future financial support from the RI-INBRE
Program and/or access to its Core Facilities and services.
Please provide one set of the
abstracts and accepted/published manuscripts and PMID# of each
manuscript that acknowledges the RI-INBRE grant to: RI-INBRE Program
office, 495J, College of Pharmacy, 7 Greenhouse Road, University of
Rhode Island, Kingston, RI 02881. You may also send the items by e-mail
to:
riinbre@etal.uri.edu.All such abstracts and publications are reported to
NIH in our Annual Progress Report which is due at the end of February
each year
Your cooperation in this matter is greatly appreciated.
